$745 | Single User
$2595 | Site License
$5195 | Global License

Academic Detailing: Pharma Fights Back
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Jan 2012 | 2 | In Stock
Related Topics: FDA , GlaxoSmithKline , Healthcare , Pfizer

Introduction

Introduction


Ever since it was introduced three decades ago, academic detailing—which now increasingly uses pharma’s sales techniques to educate physicians—has posed a difficult issue for the industry. Governed by a different set of rules, academic detailing is changing the way pharma approaches sales.


While the FDA has in recent years clamped down on what pharma can say about their drugs and introduced stringent new transparency rules, the same laws do not apply to academic detailers. And as the use of academic detailing increases in the US, where the Agency for Healthcare Research and Quality (AHRQ) has poured almost million into the practice, there are increasing concerns over the underlying motivation for its use, in light of tighter public drug budgets.


Scope


Report Overview

In Academic Detailing: Pharma Fights Back, FirstWord Dossier examines the use of academic detailing to educate physicians and asks what impact the practice is having on the pharmaceutical industry. The report questions not only the different rules for the industry and academic detailers, but under what conditions the approach works best and how pharma can fashion its response depending on whether the messages are favourable or not. Based on expert interviews, the report also reveals new marketing approaches such as changing compensation structures for sales staff and the increasing use of MSL teams. Incorporating four cases studies, the dossier offers insight into how pharma can stay abreast of what prescribers are hearing—and how it can be managed.


Highlights


Key Report Features


  • Complete overview of the practice of academic detailing

  • The AHRQ’s approach given its growing body of comparative effectiveness research

  • Discussion of the industry’s two-part strategy for ‘fighting back’

  • Insight into adept new marketing approaches to work with academic detailing

  • Four revealing case studies

  • Puchase Reasons


    Key Benefits


  • Expert insight from 15 industry voices into academic detailing

  • Fulsome discussion on how the industry is overcoming the challenges academic detailing presents

  • Specific examples showing how new marketing approaches can work

  • Key Questions Asked


  • How is academic detailing changing pharma’s sales effort?

  • What are the central challenges it presents to the industry?

  • In light of the different regulatory guidelines governing academic detailers and the industry, what is being done to level the playing field?

  • Who Would Benefit From This Report?


  • Senior sales directors

  • Medical affairs directors

  • Medical science liaisons

  • Key account and territory managers

  • Marketing, brand and sales managers

  • Business development executives

  • Regulatory and government affairs professionals


  • Key quotes


    “Academic detailing is not just a ‘say no to drugs’ programme. It begins with the assumption that prescribing is one of the most useful and challenging things we doctors do, and we crave accessible, unbiased data about the drugs we prescribe.” – Dr Jerry Avorn of Harvard Medical School


    “Academic detailers are looking to provide evidence-based information to the people they’re seeing. The reality is that we’re all striving for the same goal, which is to ensure that the patient at the end of the day receives appropriate care.” – Mark Ferdinand, vice-president, Canada's Research-Based Pharmaceutical Companies


    “I think the trick is to know (a) that academic detailing is happening, and (b) how to have that implying any affiliations. Just to be aware makes you a better partner for your customer, better able to understand their perspective and meet their needs.” – Dr Angela Bakker Lee, managing principal, ZS Associates


    Expert Views


  • Alan Bennett, counsel, Medical Information Working Group

  • Dr Carolyn M Clancy, director, US Agency for Healthcare Research & Quality

  • Dr Anthony V Dallas, jr, chief medical officer, CareHere

  • Dr Robert Dubois, chief science officer, National Pharmaceutical Council

  • Mark Ferdinand, vice-president, Canada's Research-Based Pharmaceutical Companies

  • Dr Michael Fischer, president, National Academic Detailing Resource Centre

  • Sarita Harris, principal, Atiras Group

  • Dr Angela Bakker Lee, managing principal, ZS Associates

  • James Millar, vice-president, GlaxoSmithKline

  • Dr Barry Patel, president, Total Therapeutic Management

  • Dr Eleanor Perfetto, senior director, reimbursement and regulatory affairs, Pfizer

  • Dr Robert Popovian, senior director, advocacy and professional relations, Pfizer

  • Marjorie Powell, assistant general counsel, Pharmaceutical Manufacturers & Research of America

  • Dr Scott R Smith, senior fellow, US Agency for Healthcare Research & Quality

  • Cameron Tew, executive director, research, Best Practices
  • Table of Contents
    for Academic Detailing: Pharma Fights Back [Published by FirstWord Pharma]

    • 1. Executive Summary

      2.The concept of academic detailing

      2.1. Pharma’s selling strengths

      2.2. Learning from pharma

      2.3. Defining the technique

      2.4. Recalcitrance to change

      3.Learning from the academics 1

      3.1.The practice of academic detailing

      3.2. Federal government

      3.3. Does academic detailing work?

      3.4. Pharma’s concerns

      3.5. OK for now

      3.6. AHRQ’s approach

      3.7. Cause for worry

      3.8. Different rules for different detailers

      4.Learning from the academics 2

      5.Levelling the playing field

      5.1. Fighting back: the regulatory route

      5.2. Fighting back: the litigation route

      6.Learning from the academics 3

      7.New marketing approaches

      7.1. Changing compensation structure

      7.2. Medical science liaison teams

      7.3. Segmenting the sales effort

      7.4. Aiding the patient dialogue

      7.5. Segmentation of sales force?

      7.6. Piggybacking the useful message

      8.Learning from the academics 4

      9.Acknowledgements

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    2 |

    Number of Pages

    35

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Smart Education and Learning Market by Product (Hardware, Software, Service, Educational Content), User (Academic, Corporate), Learning Mode (Collaborative, Virtual Instructor, Simulation, Adaptive, Social, Blended), and Region - Global Forecast to 2021
    “Increasing eLearning in the corporate and academic setups and widespread government initiatives is ...
    06 Dec 2016 by MarketsandMarkets USD $7,150 More Info
    Global Academic and Non-Profit Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
    Global Academic and Non-Profit Partnering Terms and Agreements 2010 to 2016 report provides a detail...
    01 Oct 2016 by Current Partnering USD $2,995 More Info
    U.S. Radiation Dose Management Market. By Product Type (Software, Services), Application (Computed Tomography, Fluoroscopy), End User (Hospitals, Diagnostic Centers, Research Institutes & Academic Medical Centers)- FORECAST TO 2020
    The U.S. radiation dose management market is projected to grow from USD 33.7 million in 2015 to USD ...
    01 Apr 2016 by MicroMarketMonitor USD $2,650 More Info
    U.S. Radiation Dose Management Market. By Product Type (Software, Services), Application (Computed Tomography, Fluoroscopy), End User (Hospitals, Diagnostic Centers, Research Institutes & Academic Medical Centers)- FORECAST TO 2020
    The U.S. radiation dose management market is projected to grow from USD 33.7 million in 2015 to USD ...
    01 Apr 2016 by MarketsandMarkets USD $2,650 More Info
    Israel Bio-pharma Research Market [Product (Consumables-Assay, Kits and Reagent, Cell Line, Instrument {Separation, Imaging}, Software, Services)], [End User (Biotechnology/Biopharmaceutical Company/ CROs, Academic and Research institute)]- Forecast to 2020
    The purpose of this report is to cover the definition, description, and forecast of the Israel bio-p...
    01 Oct 2015 by MicroMarketMonitor USD $2,650 More Info
    Israel Bio-pharma Research Market [Product (Consumables-Assay, Kits and Reagent, Cell Line, Instrument {Separation, Imaging}, Software, Services)], [End User (Biotechnology/Biopharmaceutical Company/ CROs, Academic and Research institute)]- Forecast to 2020
    The purpose of this report is to cover the definition, description, and forecast of the Israel bio-p...
    01 Oct 2015 by MarketsandMarkets USD $2,650 More Info
    Asia Pacific Learning Management Systems Market by Product (Management -Content, Student, Performance, Collaboration, Admin), by User (Academic, Corporate), by Vertical (BFSI, Govt, Healthcare, Retail, Telecom), by Geography - Analysis and Forecast to 2019
    As organizations across various verticals gradually understand the essence of a continuous learning,...
    16 Jun 2015 by MarketsandMarkets USD $2,650 More Info
    North America Learning Management Systems Market by Product (Content Management, Student Management, Performance Management, Collaboration, Administration), by User (Academic, Corporate), by Vertical, by Geography - Analysis and Forecast to 2019
    The North American learning management systems market is estimated to witness a CAGR of 23.1% during...
    01 Jun 2015 by MarketsandMarkets USD $2,650 More Info
    Middle East & Africa Learning Management System Market by Product (Student Management, Content Management, Performance Management, Administration, Collaboration), by Users (Corporate, Academic), by Deployment, by Country – Analysis and Forecast to 2019
    The Middle East and Africa Learning Management Systems market is estimated to grow at a CAGR of 28.6...
    30 Apr 2015 by MarketsandMarkets USD $2,650 More Info
    Molecular Weight Marker Market by Products (DNA, RNA, Protein Ladders), Type (Prestained, Specialty), Application (PCR, Western Blotting, Gel Extraction), & End User (Academic Institutes, Pharmaceutical Companies, CRO) - Global Forecast to 2019
    The global molecular weight markers market comprises of DNA, Protein and RNA markers. The molecular ...
    05 Feb 2015 by MarketsandMarkets USD $5,650 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Academic Detailing: Pharma Fights Back [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...